MIF and diabetes mellitus: As shown in Figure 5, the serum levels of MIF in the following five group patients were examined: pancreatic cancer patients without diabetes, pancreatic patients with more than two years history of diabetes, pancreatic patients with less than two years history of diabetes (new-onset diabetes), healthy subjects with normal fasting glucose, and T2DM patients (without any other immune diseases or tumor) diagnosed within in two years.